Charles River Laboratories International, Inc.
NYSE:CRLMedical - Diagnostics & Research
-$2.45 today
- Market cap
- $15.97B
- Beta
- 1.45
- P/E (TTM)
- -48.3
- EPS (TTM)
- -$3.77
Volume 0.52M
Average 0.86M
CRL Common Stock Repurchased
Cash spent buying back the company's own shares.
Charles River Laboratories International, Inc.NYSE: CRL
Common Stock Repurchased · Q2 FY2026 · quarter ended Jun 2026
Common stock repurchased growth accelerates
Q2 FY2026 common stock repurchased of $115.6M (cash outflow) rose 1472.3% year over year, ahead of the -29.8% change in trailing-twelve-month common stock repurchased. Sequentially, it fell 44.5% from the prior quarter. Over 3 fiscal years it compounded at +110.5% a year.
Context
- Common stock repurchased amounted to 9.0% of revenue in FY2025, up 6.0 pp from a year earlier.
- Common stock repurchased grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +1472.3% holds above the trailing-twelve-month pace of -29.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Repurchased history
USD · from the cash flow
- Latest · FY2025
- (360.67M) USD
- Year-over-year change
- -202.6%
| Period | Period end | Common Stock Repurchased | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-27 | (360.67M) | -202.6% |
| FY2024 | 2024-12-28 | (119.18M) | -393.4% |
| FY2023 | 2023-12-31 | (24.16M) | +37.5% |
| FY2022 | 2022-12-31 | (38.65M) | +5.1% |
| FY2021 | 2021-12-31 | (40.71M) | — |
Common Stock Repurchased vs competitors
How CRL compares with its peers on the latest reported figures
- CRL's LTM Jun 2026 common stock repurchased of $324.07M is the 2nd largest of the 4 companies compared; the peer median is $294.76M.
- Its year-over-year change of -29.8% is the 3rd highest of 4, against a peer median of -25.0%.
- Common stock repurchased amounts to 8.1% of revenue for CRL, versus a peer median of 10.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $765.37M | -25.0% | +95.8% | 9.3% | |
| LTM Jun 2026 | $324.07M | -29.8% | +110.5% | 8.1% | |
| LTM Sep 2026 | $294.76M | -72.9% | +2.7% | 10.4% | |
| LTM Mar 2026 | $82.67M | +1049.5% | +143.2% | 19.7% | |
| Peer median (excluding CRL) | $294.76M | -25.0% | +95.8% | 10.4% | |
Competitors are the stored peer set for CRL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 398.84M | 492.61M | 480.37M | 25.29M | (142.16M) |
| Depreciation & Amortization | 265.54M | 303.87M | 314.12M | 361.74M | 403.31M |
| Deferred Income Tax | (24.01M) | (35.88M) | (50.9M) | (67.43M) | (75.29M) |
| Stock-Based Compensation | 71.47M | 73.62M | 72.05M | 69.89M | 71.08M |
| Change in Working Capital | 42.94M | (152.55M) | (102.38M) | (30.33M) | 14.08M |
| Accounts Receivables | (26.63M) | (150.57M) | (33.43M) | 21.61M | 35.74M |
| Inventory | (25.16M) | (78.52M) | (62.3M) | 16.8M | (48.78M) |
| Accounts Payables | 44.9M | (2.65M) | (20.43M) | (14.27M) | 2.87M |
| Other Working Capital | 49.83M | 79.19M | 13.78M | (54.47M) | 24.25M |
| Other Non-Cash Items | 6.01M | (62.02M) | (29.36M) | 375.41M | 466.63M |
| Operating Cash Flow | 760.8M | 619.64M | 683.9M | 734.58M | 737.65M |
| Capital Expenditures | (228.77M) | (324.73M) | (318.53M) | (232.97M) | (219.15M) |
| Acquisitions (Net) | (1.17B) | (120.12M) | (194.79M) | (5.48M) | 17.44M |
| Purchases of Investments | (45.56M) | (158.27M) | (54.22M) | (52.88M) | (20.08M) |
| Sales of Investments | 6.53M | 4.55M | 6.67M | 41.69M | 9.1M |
| Other Investing Activities | 264K | (9.35M) | (2.29M) | 4.55M | 3.36M |
| Investing Cash Flow | (1.44B) | (607.92M) | (563.16M) | (245.09M) | (209.32M) |
| Debt Repayment | 669.98M | 19.79M | (75.32M) | (412.19M) | (121.78M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 714K |
| Common Stock Repurchased | (40.71M) | (38.65M) | (24.16M) | (119.18M) | (360.67M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 43.32M | (23.54M) | 13.96M | (19.56M) | (54.98M) |
| Financing Cash Flow | 672.6M | (42.4M) | (85.52M) | (550.93M) | (536.73M) |
| Effect of Forex Changes | 17.73M | 25.58M | 8.04M | (17.47M) | 18.83M |
| Net Change in Cash | 13.2M | (5.1M) | 43.27M | (78.91M) | 10.43M |
| Free Cash Flow | 532.03M | 294.91M | 365.37M | 501.61M | 518.49M |
Charles River Laboratories International, Inc.
NYSE:CRL
Intrinsic Alpha fair value
Locked
Current Price
$333.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.